Overview and Scope
D-dimer testing refers to laboratory blood testing that measures the d-dimer level in the bloodstream. D-dimer is a protein fragment produced when a blood clot breaks down in the body. The test is primarily used to help diagnose or rule out the presence of blood clots, particularly in conditions such as deep vein thrombosis (DVT) or pulmonary embolism (PE).
Sizing and Forecast
The d dimer testing market size has grown strongly in recent years. It will grow from $1.38 billion in 2023 to $1.46 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to emergence of thrombosis research, improvements in laboratory techniques, clinical validation of d-dimer as a marker, shift in diagnostic protocols.
The d dimer testing market size is expected to see steady growth in the next few years. It will grow to $1.77 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing geriatric population, growth in point-of-care testing (poct), integration with risk assessment algorithms, increased awareness and education campaigns, regulatory guidance and standardization. Major trends in the forecast period include biomarker combinations for enhanced diagnosis, focus on rapid and accurate results, d-dimer testing in covid-19 management, remote monitoring and home-based testing kits, continuous monitoring and serial testing.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/d-dimer-testing-global-market-report
Segmentation & Regional Insights
The d dimer testing market covered in this report is segmented –
1) By Test: Clinical Laboratory Tests, Point-Of-Care Tests
2) By Product: Analyzers, Reagents And Consumables
3) By Method: Enzyme-linked Immunosorbent Assay (ELISA), Latex-enhanced Immuno-turbidimetric Assays, Fluorescence Immunoassays, Other Testing Method
4) By Application: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Disseminated Intravascular Coagulation (DIC), Other Application
5) By End-User: Hospitals, Academic And Research Institutes, Diagnostic Centers, Other End-User
North America was the largest region in the D dimer testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the d dimer testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=12341&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of cancer is expected to propel the growth of the d-dimer testing market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. D-dimer testing is primarily used to help diagnose, monitor, and treat cancer patients and assess the risk of blood clot formation. It monitors thrombotic events in various clinical settings. For instance, in January 2022, according to research published by the American Cancer Society, a US-based health organization, 609,360 cancer deaths and 1.9 million new cancer cases are anticipated in the US in 2022. It is about 1,670 fatalities each day. Therefore, the increasing prevalence of cancer is driving the growth of the d-dimer testing market.
Key Industry Players
Major companies operating in the D dimer testing market report are Kaiser Foundation Health Plan Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, Becton Dickinson And Company (BD), Laboratory Corporation, Quest Diagnostics Inc., bioMérieux SA, Beckman Coulter Inc., Quidel Corporation, QuidelOrtho Corporation, Sysmex Corporation, Horiba Ltd., Werfen SA, Helena Laboratories Corporation, Abcam PLC, LumiraDx Limited, Sekisui Diagnostics LLC, Personalabs, Sekisui Diagnostics LLC, Diagnostica Stago S.A.S., RayBiotech Inc., CTK Biotech Inc., Diazyme Laboratories Inc., AdvaCare Pharma USA, UCP Biosciences Inc., Unbound Medicine Inc., AccuBioTech Co Ltd., Response Biomedical Corporation.
The d dimer testing market report table of contents includes:
1. Executive Summary
2. D Dimer Testing Market Characteristics
3. D Dimer Testing Market Trends And Strategies
4. D Dimer Testing Market – Macro Economic Scenario
5. Global D Dimer Testing Market Size and Growth
.
.
.
31. D Dimer Testing Market Other Major And Innovative Companies
32. Global D Dimer Testing Market Competitive Benchmarking
33. Global D Dimer Testing Market Competitive Dashboard
34. Key Mergers And Acquisitions In The D Dimer Testing Market
35. D Dimer Testing Market Future Outlook and Potential Analysis
36.Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
